Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Respondent of NAD inquiry, marketer of Xenadrine EFX is Cytodyne LLC, not Cytodyne, as recently reported (1"The Tan Sheet" March 15, 2004, In Brief). The original Cytodyne licensed rights to its products to newly created entity Cytodyne LLC, a subsidiary of Phoenix Labs, in 2003 (2"The Tan Sheet" June 23, 2003, p. 13). The entity formerly known as Cytodyne is now called Nutraquest, which was not involved in the events related to the NAD inquiry...

You may also be interested in...


FTC is reviewing advertising for ephedra-free weight-loss product, previous marketer Cytodyne told the National Advertising Division of the Council of Better Business Bureaus in response to an inquiry, according to a recent NAD release. As a result, the firm declined to take part in NAD's request for substantiation of a number of claims including the statement that Xenadrine-EFX "was clinically tested against two leading ephedra-based thermogenic supplements and outperformed them for both the boosting of metabolism, and resulting caloric expenditure." Marketer of the supplement is now known as Nutraquest...

Cytodyne Products’ Distribution And Sales Rights Licensed To Phoenix Labs

Cytodyne Technologies has licensed the distribution, marketing and sales rights to its products to Apex Fitness Group's Phoenix Labs division, the firms announced June 16

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts